Assessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities
Launched by PENUMBRA INC. · Sep 25, 2019
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient age ≥ 18 years
- • Patient having embolization of intracranial aneurysms
- • WAVE Extra Soft Coil is final finishing coil
- • Penumbra SMART COIL System accounts for at least 75% of total number of coils implanted
- • Informed consent obtained per Institutional Review Board/Ethics Committee (IRB/EC) requirements
- Exclusion Criteria:
- • Life expectancy less than 1 year
- • Patient previously enrolled in the SURF Study
- • Known multiple intracranial aneurysms requiring treatment during index procedure
- • Patient is unwilling or unable to comply with protocol follow up schedule and/or based on the Investigator's judgment the patient is not a good study candidate
- • Participation in an interventional drug or device study that may confound the results of the study
About Penumbra Inc.
Penumbra Inc. is a leading medical technology company focused on developing innovative solutions for neurovascular and peripheral vascular conditions. With a commitment to advancing patient care, Penumbra specializes in the design and manufacture of devices that enhance the treatment of complex medical conditions, including stroke and embolism. The company leverages cutting-edge technology and rigorous clinical research to deliver products that improve outcomes and enhance the quality of life for patients. Penumbra's dedication to innovation and collaboration with healthcare professionals positions it at the forefront of the medical device industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Chicago, Illinois, United States
Dallas, Texas, United States
Pittsburgh, Pennsylvania, United States
Newport News, Virginia, United States
Valhalla, New York, United States
Danville, Pennsylvania, United States
Toronto, Ontario, Canada
New York, New York, United States
Oklahoma City, Oklahoma, United States
Tampa, Florida, United States
Basel, , Switzerland
Oklahoma City, Oklahoma, United States
Greenville, North Carolina, United States
Tampa, Florida, United States
Greenville, South Carolina, United States
Charleston, South Carolina, United States
New Orleans, Louisiana, United States
Miami, Florida, United States
Manhasset, New York, United States
Philadelphia, Pennsylvania, United States
Toledo, Ohio, United States
Dresden, , Germany
Chemnitz, , Germany
Thousand Oaks, California, United States
Manhasset, New York, United States
Stony Brook, New York, United States
Indianapolis, Indiana, United States
Buffalo, New York, United States
Indianapolis, Indiana, United States
Chattanooga, Tennessee, United States
Lübeck, , Germany
Toronto, Ontario, Canada
Barcelona, , Spain
Lakewood, Colorado, United States
Wyoming, Michigan, United States
Mcallen, Texas, United States
Dothan, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
La Mesa, California, United States
Englewood, Colorado, United States
New Haven, Connecticut, United States
Tampa, Florida, United States
Joliet, Illinois, United States
Bridgeton, Missouri, United States
Knoxville, Tennessee, United States
Plano, Texas, United States
Calgary, , Canada
Bremen, , Germany
Novara, , Italy
San Sebastián, , Spain
Englewood, Colorado, United States
Miami, Florida, United States
Plano, Texas, United States
Toronto, , Canada
Patients applied
Trial Officials
Clemens M Schirmer, MD
Principal Investigator
Geisinger Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials